Industry funding common in recent influential clinical trials

Embargoed until: Publicly released: 2023-11-15 03:00

International

Photo by Anastasiia Gudantova on Unsplash

A study of 600 of the most-cited clinical trials published after 2018 found that industry involvement was very common with 68% receiving industry funding, 59% having industry authors, and 47% involving industry analysts. The researchers found industry-sponsored studies typically favoured the sponsor. The researchers say that while their results do not necessarily prove industry bias, they suggest that enhanced independence in the conduct and reporting of these influential studies and maximal transparency are needed to alleviate concerns about bias.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Sapienza University of Rome, Italy, Stanford University, USA

Funder: The work of Dr Ioannidis is supported by an unrestricted gift from Sue and Bob O’Donnell. Mr Papamanolis is supported by a fellowship from the Department of Bioengineering at Stanford University. Dr Siena reported receiving grants from the European Network Staff Exchange for Integrating Precision Health in the Health Care Systems (EXACT), a Marie Skłodowska-Curie Research and Innovation Staff Exchange project during the conduct of this study work. Mr Papamanolis reported receiving personal fees from HeartFlow outside the submitted work. Dr Bellomo reported receiving grants from the EXACT during the conduct of this study. No other disclosures were reported.

Media Contact/s

Contact details are only visible to registered journalists.